Roivant reports Immunovant thyroid eye disease Phase 3 failure, new LPP trial
Roivant said its Immunovant unit's two Phase 3 studies of batoclimab in thyroid eye disease failed to meet their primary endpoint, and it started a new Phase 2b/3 trial of brepocitinib in lichen planopilaris at Priovant. The filing also gave preliminary cash and marketable securities of about $4.3 billion as of March 31, 2026, and buybacks of about $109.7 million in the quarter, while the fiscal year audit is still ongoing.
Key points
- Immunovant's two Phase 3 batoclimab studies in thyroid eye disease each failed to meet the primary endpoint of at least 2mm proptosis responder rate at Week 24; no new safety signals were identified.
- Priovant began a seamless Phase 2b/3 trial of brepocitinib in lichen planopilaris, with first subjects enrolled in March 2026.
- Preliminary cash, cash equivalents and marketable securities were about $4.3 billion as of March 31, 2026.
- Roivant repurchased 3,956,362 common shares for about $109.7 million (excluding fees and commission) in the three months ended March 31, 2026.
The filing
Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 1:10 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on April 02, 2026.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.